VerteLoc™ Tops 500 Surgical Procedures, VGI Announces VerteLX™ and Seeks Potential Investors for Growth
The VerteLoc™ Minimally Invasive Spine Stabilization system has now been implanted in more than 500 patients across the United States. Surgeon acceptance of the surgical procedure continues to drive record growth. VGI will pursue its first FDA 510K on another device, VerteLX™, for the...
Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
EXTON, Penn., July 1 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma Corporation to express and develop therapeutic monoclonal antibodies for the potential
treatment of various forms of can...
Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer
- Dosimetry Study Results Show Greater Than 300-Fold More Radiation Delivered to Tumor as Compared to Other Normal Organs -
- All Patients in the First Two Cohorts Have Met or Exceeded the Expected Median Survival Time for Recurrent GBM Patients -
TORONTO and TUSTIN, Calif., June ...
New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
COLLEGEVILLE, Pa., June 11 /PRNewswire-FirstCall/ -- New data from Phase 3 European clinical trials reinforce that Wyeth's (NYSE: WYE ) investigational pneumococcal vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine, 13-valent [Adsorbed]), has the potential
to provide cov...
PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
KVISTGAARD, Denmark, June 1 /PRNewswire-FirstCall/ -- Detailed data from
a randomized Phase 2 study with PROSTVAC(TM) were presented Saturday at the
ASCO Annual Meeting in Orlando. The presentation was made by Philip Kantoff
MD, Professor of Medicine, Harvard Medical School , and the Dana-Far...
BIO International Convention 2009: Research Location Germany Presents Potential in Regenerative Medicine
ATLANTA, May 20 /PRNewswire/ -- Germany will present itself as one of the
world's leading regenerative medicine research locations at this year's BIO
International Convention. Under the "Breakthroughs in Regenerative Medicines
in Germany" banner, German experts will provide invaluable insight ...
CEL-SCI's L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
Peptide-based vaccines could prove efficacious for both prophylactic and therapeutic treatments
VIENNA, Va., April 28 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM ) announced today that preclinical studies have demonstrated that vaccines utilizing its proprietary L.E.A.P.S....
CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
Technology also has potential
to fight cancer, rheumatoid arthritis, as well as enhance the effectiveness of vaccines
VIENNA, Va., April 27 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM ) announced today the presentation of data at the 11th annual National Foundation of Infe...
Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations
AMSTERDAM, April 8 /PRNewswire/ -- Biopharmaceutical company Kiadis
Pharma reported preliminary clinical data on ATIR(TM) showing its potential
in mismatched bone marrow transplantations. Data was presented by the
company's principal investigator Dr. Denis Claude Roy during the prestigious
Improved Cryopreservation Outcomes in Potential $100B Tissue Engineering Market Enabled by BioLife Solutions CryoStor(TM)
Independent, Comparative Evaluation by Leading Research Centers in Germany and Portugal Indicates Significant Biopreservation Advantages of Serum-Free, Pre-Formulated CryoStor
BOTHELL, Wash., March 10 /PRNewswire-FirstCall/ -- BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading deve...
Researchers discover a potential on-off switch for nanoelectronics
Berkeley, CA - As electronic circuits shrink from finely etched lines in silicon wafers to nearly elusive proportions, researchers at the U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) and Columbia University are studying how electrons flow through a molecular jun...
Research highlights potential for improved solar cells
LOS ALAMOS, New Mexico, February 10, 2009A team of Los Alamos researchers led by Victor Klimov has shown that carrier multiplicationwhen a photon creates multiple electronsis a real phenomenon in tiny semiconductor crystals and not a false observation born of extraneous effects that mimic carrier ...
Accidental discovery has potential for new applications in packaging
CLEVELAND A recent discovery at Case Western Reserve University may help keep food and drugs safer and fresher longer and electronic equipment dryer and more secure than ever before all at a lower cost.
The finding involves a nanotechnology-based technique to block the transport of damaging g...
Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
ST. LOUIS, Feb. 4 /PRNewswire-FirstCall/ -- Illinois, a state that hosted
the first field trial of biotechnology crops more than two decades ago, made
history again this week with the first delivery to a dealer of the next
generation of higher yielding soybean technology. The technology, Mons...
XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives
VALLEY COTTAGE, N.Y., Jan. 28 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB , TASE: XTL) today announced an update to its December 8, 2008 press release regarding the Company's activities in seeking to acquire potential
assets or to identify a company to merge into or with ...
Novel Diabetes Drug Discovery Has Potential to Reverse Disease
WYNNEWOOD, Pa., Jan. 27 /PRNewswire/ -- A study released today in Endocrine Practice (2008;14:1075), the leading peer-reviewed journal for practicing endocrinologists in the US and 65 countries, reports a ground breaking discovery with the potential
to reverse type 1 and 2 diabetes. Scientists ...
Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
SEATTLE, Jan. 14 /PRNewswire-FirstCall/ -- In meetings held in association
with the JP Morgan Healthcare Conference in San Francisco, Cell Therapeutics,
Inc. (CTI) (Nasdaq and MTA: CTIC) reviewed 2009 targeted milestones and 2008
accomplishments. CTI is seeking to obtain two new drug approvals...
Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation
PETERSBURG, Va., Jan. 6 /PRNewswire-FirstCall/ -- Star Scientific (Nasdaq :STSI) announced today that its subsidiary, Rock Creek Pharmaceuticals, Inc., in conjunction with its Star Tobacco, Inc. subsidiary, recently completed a study to determine the ability of Stonewall(R) dissolvable smokeless ...
Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias
Interim Data from a Phase 2 Clinical Trial in B-Precursor Acute Lymphoblastic Leukemia Show that Blinatumomab is Able to Eliminate Minimal Residual Disease
BETHESDA, Md., Dec. 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, propr...
RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease
First in class drug illustrates early signal of transport of key amyloid marker from brain
TSX Exchange Symbol: RVX CALGARY, Nov. 10 /PRNewswire-FirstCall/ - Resverlogix Corp.
("Resverlogix") (TSX:RVX) announced today that treatment with its lead drug
RVX-208, a first in class ApoA-I/Prebet...
Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan
Large-Scale Rapid Production, Increased Bioavailability
MOUNTAIN VIEW, Calif., Oct. 21 /PRNewswire/ -- An increased number of
diseases that are either incurable or difficult to treat allures clinicians
to the approach of stem cell therapy. Highly prized, due to their
Jellyfish Protein Shows Potential to Help With Memory
BOSTON, Oct. 15 /PRNewswire/ -- Quincy Bioscience (Madison, WI)
announces that Prevagen(R) (http://www.prevagen.com ), a dietary supplement
consisting of the jellyfish protein apoaequorin, has displayed great
potential to improve memory in healthy human subjects tested. The Prevagen
CPC of America, Inc. to Explore Strategic Alternatives; Appoints FTI Capital Advisors to Assess Potential Opportunities
SARASOTA, Fla., Sept. 29 /PRNewswire-FirstCall/ -- CPC of America, Inc.
(OTC Bulletin Board: CPCF.OB) today announced that it had retained FTI
Capital Advisors, LLC, the investment banking subsidiary of FTI Consulting,
Inc., to explore strategic alternatives for the Company.
As CPC of Americ...
Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
- Premacure to Initiate Phase II Trial for IPLEX(TM) in Retinopathy of
RICHMOND, Va. and UPPSALA, Sweden, Sept. 23 /PRNewswire-FirstCall/ --
Insmed Inc. (Nasdaq CM: INSM), a developer of follow-on biologics (FOBs)
and biopharmaceuticals, and Premacure AB, a biopharmaceutical co...
CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
PALO ALTO, Calif., Sept. 2 /PRNewswire-FirstCall/ -- CV Therapeutics,
Inc. (Nasdaq: CVTX ) announced today that the company has enrolled the first
patient in a Phase 1 trial of CVT-3619, a novel oral compound for potential
treatment of cardiometabolic diseases. The U.S. Food and Drug
Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
Collaboration Will Seek to Identify microRNAs Implicated in HIV Viral Replication and Their Function
Samples Will be Screened and Analyzed Using Rosetta Genomics' Proprietary microRNA Technologies
REHOVOT, Israel and JERSEY CITY, New Jersey, August...
John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technology's Potential to Help 'Millions of Patients'
Best-Selling Author to Devote Energies to Raising Awareness and Funds to
Advance the Use of Focused Ultrasound in Treating Cancers, Neurological, Other Serious Medical Conditions
CHARLOTTESVILLE, Va., Aug. 13 /PRNewswire/ -- The Focused Ultrasound
Surgery Foundation, found...
Penn scientists demonstrate potential of graphene films as next-generation transistors
PHILADELPHIA - Physicists at the University of Pennsylvania have characterized an aspect of graphene film behavior by measuring the way it conducts electricity on a substrate. This milestone advances the potential
application of graphene, the ultra-thin, single-atom thick carbon sheets that con...
Vermillion Retains ThinkPanmure to Assist in the Evaluation of Potential Strategic Alternatives
FREMONT, Calif., July 14 /PRNewswire-FirstCall/ -- Vermillion, Inc.
(Nasdaq: VRML ), a molecular diagnostics company, today announced that it
has engaged ThinkPanmure LLC., a global, growth-company investment bank, to
assist the Company in identifying and evaluating strategic alternatives
Addrenex Pharmaceuticals Licenses New Compound to Sciele Pharma for the Treatment of Hypertension and Other Potential Indications
DURHAM, N.C., July 1 /PRNewswire/ -- Two years after Addrenex
Pharmaceuticals set it sights on building a new class of drugs to regulate
"adrenergic excess," the small Durham company has signed its second major
deal with Sciele Pharma, this time to co-develop a new compound for
Access Pharmaceuticals Presents New Data at International Symposium Showing Company's Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
DALLAS, June 26 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC.
(OTC Bulletin Board: ACCP) announced that the Company gave an oral
presentation yesterday on its monoclonal antibody product, Angiolix(R), at
the 7th International Congress on Recombinant Antibodies, held in Dublin,
CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
Access to data may provide potential
for label expansion in the U.S.
SEATTLE, June 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
(CTI) (Nasdaq: CTIC ; MTA) announced today an agreement with Bayer Schering
Pharma to gain access to Bayer's phase III Zevalin(R) ([90Y]-ibritumomab
First semiconductor-based PET scanner demonstrates potential to aid in early diagnosis of disease
NEW ORLEANS, La.Evaluations of the first-ever prototype positron emission tomography (PET) brain scanner that uses semiconductor detectors indicate that the scanner could advance the quality and spatial resolution of PET imaging, according to researchers at SNM's 55th Annual Meeting. The prototype...
ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets
NDC #58177-320-04 & 58177-330-04 Lot Numbers listed below
ST. LOUIS, June 13 /PRNewswire/ -- ETHEX Corporation announced today
that it has voluntarily recalled specific additional lots of morphine
sulfate 60 mg extended release tablets, and specific l...
Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma
CHICAGO, June 2 /PRNewswire-FirstCall/ -- At the 44th Annual Meeting of
the American Society of Clinical Oncology (ASCO), two studies were
presented investigating the potential
utility of Zevalin(R) (Ibritumomab
Tiuxetan) radioimmunotherapy as replacement for external beam radiations or
Actress and Mom Lori Loughlin Raises Awareness About the Potential Dangers of Drowsy Driving During Allergy Season
"Clear to Drive" Campaign Urges Allergy Sufferers to Check Medicine Labels for Drowsiness Warnings Before Getting Behind the Wheel
KENILWORTH, N.J., May 6 /PRNewswire-FirstCall/ -- Summer is fast
approaching, bringing sunshine, vacation days, and trips to the beach. But
the warmer weathe...
Huge Potential in Biosimilars if Generic Providers Overcome Regulatory Hurdles
NEW YORK, April 22 /PRNewswire/ -- Some of the biggest-selling
biologics developed during the boom years in biotech of the 1980's,
including human growth hormone (hGH) and insulin, have lost patent
protection in the U.S. in 2007 or will shortly, and they represent a market
of $40 billion. This...
Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
TAMPA, Fla., April 21 /PRNewswire/ -- Sirion Therapeutics, Inc., a
privately held ophthalmic-focused biopharmaceutical company, announced
today that preclinical results for two new compounds targeted for the
treatment of retinal diseases will be presented during the 2008 Annual
Meeting of the ...
Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
RICHMOND, Va., April 10 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq:
INSM), a developer of follow-on biologics and biopharmaceuticals, today
announced receipt of a letter and questionnaire from the Chairman and
Ranking Member of the U.S. House of Representatives' Subcommittee on Health
Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
- Findings Presented at the American College of Cardiology 57th Annual Scientific Session -
FREMONT, Calif., April 8, 2008 /PRNewswire-FirstCall/ -- Vermillion,
Inc. (Nasdaq: VRML ), a molecular diagnostics company, presented data from a
study providing further confi...